肝细胞癌监测可改善肝硬化患者的早期检出、治愈性治疗接受率及生存:一项荟萃分析
该系统综述与荟萃分析检索了2014年1月至2020年7月的Medline、EMBASE数据库及全国会议摘要,纳入59项队列研究共145,396例肝细胞癌患者。肝细胞癌监测与更高的早期检出率(RR 1.86)、治愈性治疗接受率(RR 1.83)及校正领先时间偏倚后的总生存改善(HR 0.67)相关,但各汇总估计值异质性显著;监测相关身体伤害发生比例为8.8%至27.5%,多数较轻微。
要点
- 肝细胞癌监测与肝硬化患者早期检出改善相关(RR 1.86,95%CI 1.73-1.98)。
- 监测与治愈性治疗接受率提高相关(RR 1.83,95%CI 1.69-1.97)。
- 校正领先时间偏倚后监测与总生存改善相关(HR 0.67,95%CI 0.61-0.72)。
核心结论
- 肝细胞癌监测与肝硬化患者早期检出、治愈性治疗接受率及生存改善相关,但汇总估计值存在异质性。
- 现有数据提示肝细胞癌监测在肝硬化患者中具有高价值,仍需持续开展严谨研究评估获益与伤害。
研究设计与样本
- 对评估肝硬化患者肝细胞癌监测获益与伤害的队列研究进行系统综述与荟萃分析。
- 检索Medline、EMBASE数据库及全国会议摘要,时间范围为2014年1月至2020年7月。
- 纳入59项研究,共145,396例肝细胞癌患者,其中41,052例(28.2%)通过监测检出。
- 按肝细胞癌监测状态分层,采用DerSimonian and Laird随机效应模型计算汇总风险比(RR)与风险比(HR)。
主要发现
- 肝细胞癌监测与早期检出改善相关(RR 1.86,95%CI 1.73-1.98;I²=82%)。
- 肝细胞癌监测与治愈性治疗接受率提高相关(RR 1.83,95%CI 1.69-1.97;I²=75%)。
- 校正领先时间偏倚后,肝细胞癌监测与总生存改善相关(HR 0.67,95%CI 0.61-0.72;I²=78%)。
- 四项研究评估了假阳性或不确定监测结果所致的监测相关身体伤害,各研究中经历此类伤害的患者比例为8.8%至27.5%,多数伤害程度较轻。
- 无研究评估监测相关的经济或心理伤害。
关键数值与推荐
- 早期检出:监测组RR 1.86(95%CI 1.73-1.98;I²=82%)。
- 治愈性治疗接受:监测组RR 1.83(95%CI 1.69-1.97;I²=75%)。
- 总生存:监测组HR 0.67(95%CI 0.61-0.72;I²=78%),已校正领先时间偏倚。
- 监测相关身体伤害发生比例范围为8.8%至27.5%,多数较轻微。
临床怎么用
- 原文结论指出肝细胞癌监测与肝硬化患者早期检出、治愈性治疗接受率及生存改善相关。
- 原文指出仍需持续开展严谨研究评估肝细胞癌监测的获益与伤害。
局限性
- 所有汇总估计值均存在显著异质性(早期检出I²=82%,治愈性治疗I²=75%,总生存I²=78%)。
- 缺乏随机对照试验数据。
- 仅四项研究评估了监测相关身体伤害,无研究评估经济或心理伤害。
- 原文指出仍需持续开展严谨研究评估获益与伤害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we conducted a systematic review and meta-analysis of cohort studies evaluating the benefits and harms of HCC surveillance in patients with cirrhosis. METHODS: We performed a search of the Medline and EMBASE databases and national meeting abstracts from January 2014 through July 2020 for studies reporting early-stage HCC detection, curative treatment receipt, or overall survival, stratified by HCC surveillance status, among patients with cirrhosis. Pooled risk ratios (RRs) and hazard ratios, according to HCC surveillance status, were calculated for each outcome using the DerSimonian and Laird method for random effects models. RESULTS: We identified 59 studies including 145,396 patients with HCC, which was detected by surveillance in 41,052 (28.2%) cases. HCC surveillance was associated with improved early-stage detection (RR 1.86, 95% CI 1.73-1.98; I2 = 82%), curative treatment receipt (RR 1.83, 95% CI 1.69-1.97; I2 = 75%), and overall survival (hazard ratio 0.67, 95% CI 0.61-0.72; I2 = 78%) after adjusting for lead-time bias; however, there was notable heterogeneity in all pooled estimates. Four studies examined surveillance-related physical harms due to false positive or indeterminate surveillance results, but no studies examined potential financial or psychological harms. The proportion of patients experiencing surveillance-related physical harms ranged from 8.8% to 27.5% across studies, although most harms were mild in severity. CONCLUSION: HCC surveillance is associated with improved early detection, curative treatment receipt, and survival in patients with cirrhosis, although there was heterogeneity in pooled estimates. Available data suggest HCC surveillance is of high value in patients with cirrhosis, although continued rigorous studies evaluating benefits and harms are still needed. LAY SUMMARY: There has been ongoing debate about the overall value of hepatocellular carcinoma (HCC) screening in patients with cirrhosis given the lack of data from randomized-controlled trials. In a systematic review of contemporary cohort studies, we found that HCC screening is associated with improved early detection, curative treatment receipt, and survival in patients with cirrhosis, although there were fewer data quantifying potential screening-related harms. Available data suggest HCC screening is of high value in patients with cirrhosis, although continued studies evaluating benefits and harms are still needed.
引用
- Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022. PMID: 35139400. doi:10.1016/j.jhep.2022.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。